Referred to the House Committee on Energy and Commerce.
Requires the HHS Assistant Secretary for Planning and Evaluation to conduct an annual, 10-year study of State-level health care competition and consolidation. The study must consult with FTC and DOJ antitrust, collect data on licensing, mergers, facility counts, alternative insurance forms, certificates of need/advantage, and compute Herfindahl–Hirschman Indexes.
Liberals emphasize study as foundation for antitrust action.
Relative to its intended legislative type, this bill is a well-scoped and specifically detailed reporting mandate that clearly assigns responsibility, enumerates metrics, requires interagency consultation, and mandates annual public reporting over a defined 10-year period, but it omits funding authorization and detailed provisions for handling confidential data, data quality, and operational logistics.
Requires the HHS Assistant Secretary for Planning and Evaluation to conduct an annual, 10-year study of State-level health care competition and consolidation.
The study must consult with FTC and DOJ antitrust, collect data on licensing, mergers, facility counts, alternative insurance forms, certificates of need/advantage, and compute Herfindahl–Hirschman Indexes.
Each year HHS must report to specified Congressional committees and publish reports and publicly accessible interactive datasets online.
Narrow, administrative, and bipartisan-leaning scope increases chances, but lack of funding authorization and competing priorities reduce near-term probability.
Relative to its intended legislative type, this bill is a well-scoped and specifically detailed reporting mandate that clearly assigns responsibility, enumerates metrics, requires interagency consultation, and mandates annual public reporting over a defined 10-year period, but it omits funding authorization and detailed provisions for handling confidential data, data quality, and operational logistics.
Liberals emphasize study as foundation for antitrust action.
These are examples from the analysis, not a ranked list of the most-affected groups.
Liberals emphasize study as foundation for antitrust action.
Likely supportive because the bill creates systematic, public data to document consolidation and anticompetitive patterns.
They will view it as a necessary evidence base for stronger antitrust enforcement and protections for patients and workers, while noting the bill does not itself mandate remedies.
Generally favorable as an evidence-driven, consultative approach to a complex policy area.
Will emphasize careful methodology, funding clarity, and nonpartisan presentation; supportive if the study is adequately resourced and avoids duplicative state-federal conflict.
Skeptical of expanded federal involvement in state healthcare markets; accepts factual study in principle but worries about federal overreach, regulatory mission creep, and potential misuse to block mergers.
May appreciate that alternative plans are examined, but cautious overall.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Narrow, administrative, and bipartisan-leaning scope increases chances, but lack of funding authorization and competing priorities reduce near-term probability.
The bill has not accumulated any surfaced votes yet.
Liberals emphasize study as foundation for antitrust action.
Narrow, administrative, and bipartisan-leaning scope increases chances, but lack of funding authorization and competing priorities reduce n…
Relative to its intended legislative type, this bill is a well-scoped and specifically detailed reporting mandate that clearly assigns responsibility, enumerates metrics, requires interagency consultation, and mandates…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.